Amarin's Vascepa Associated With Stroke Reduction

Amarin Corporation plc AMRN has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Conference 2021.

• The REDUCE-IT STROKE analyses examined stroke rates across the enrolled patient population (n=8179).
• The study showed 28% and 32% significant reductions in first and total strokes, demonstrated with Vascepa compared to placebo.
• Reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk.
• Consistent reductions in overall stroke and ischemic stroke were observed across multiple subgroups.
• Price Action: AMRN shares are trading 3.4% higher at $6.70 in market trading hours on the last check Wednesday.